CPT 69799 is referenced in 4 tracked payer policy changes from Sentara Health Plans, Excellus BlueCross BlueShield, and 1 other payer. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for CPT 69799 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.
Starting January 1, 2027, Sentara Health Plans will require prior authorization for a long list of codes on Virginia commercial plans, including self-funded (ASO) plans, and for code 88380 on commercial, Medicaid and Medicare products, plus code 22860 on Medicare products. Sentara will also stop covering a separate list of codes on Virginia commercial and self-funded plans.
Excellus BlueCross BlueShield policy 7.01.101 considers balloon dilation of the Eustachian tube (BDET), unilateral or bilateral, medically appropriate for chronic obstructive Eustachian tube dysfunction in adults 18 years or older who meet all listed criteria. The criteria include an abnormal tympanogram (Type B or C), an abnormal tympanic membrane on examination, other causes of aural fullness ruled out, aural fullness and pressure with hearing loss or otalgia, symptoms lasting three months or longer that are continuous, and no contraindication such as patulous ETD or dehiscence of the carotid artery canal. Failure of medical management of coexisting conditions is part of the treatment history where applicable. BDET is investigational as a repeat procedure, when performed with tympanoplasty or other middle ear surgery, for transtympanic BDET, for ages 17 and younger, and for extrinsic causes of ETD. BDET can only be performed with an FDA-approved balloon dilation device or system. The policy notes that CMS does not address balloon dilation of the Eustachian tube in national or regional Medicare coverage determinations. The current effective date is July 16, 2026, and the annual review states policy intent is unchanged.
Balloon dilation of the eustachian tube for chronic obstructive eustachian tube dysfunction may be considered medically necessary for adults age 22 and older with obstructive symptoms lasting 12 months or longer that significantly affect quality of life, when all listed criteria are met. Balloon dilation is considered investigational if the criteria are not met. The 03/15/2025 revision updated the device description and removed CPT code 69799 from the code reference, and the policy statements are unchanged.
Semi-implantable and fully implantable middle ear hearing aids are considered investigational under this policy. Two semi-implantable devices, the Vibrant Soundbridge and the Maxum System, and one fully implantable device, the Esteem Implantable Hearing System, have FDA approval. The Esteem device is indicated for adults 18 years of age or older with stable bilateral sensorineural hearing loss.
Watch 69799
Get one email when a payer policy names 69799, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.
See every payer rule for 69799
Prior authorization lists, coverage criteria, NCCI edits and Medicare coverage articles for 69799 in one place.
Get alerts for changes like this
Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.